Ziopharm Oncology Names James Huang to Board of Directors

Nachrichtenquelle: globenewswire
22.07.2020, 14:30  |  116   |   |   

Industry veteran entrepreneur with 20+ years’ experience founding and financing successful, innovative biotech companies including GenScript and Legend Biotech

Managing Partner at Kleiner Perkins Caufield & Byers China; Founder of Panacea Venture, funding source for Ziopharm’s joint venture Eden BioCell

BOSTON, July 22, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP), today announced the appointment of James Huang to the Company’s Board of Directors. Mr. Huang is currently a Managing Partner at Kleiner Perkins Caufield & Byers (KPCB) China and has founded and financed several innovative life sciences companies, including GenScript, Legend Biotech and Zai Lab. He is also Founding Partner of Panacea Venture, which formed TriArm Therapeutics, the funding partner for Ziopharm’s joint venture, Eden BioCell.  

“We are delighted to welcome James to Ziopharm’s Board of Directors. He has an unparalleled track record of success in creating and building value with life science companies in and around China,” said Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm. “James shares our vision for harnessing the power of the non-viral Sleeping Beauty system to commercialize novel treatments for cancer, and his vision and business acumen have been instrumental to the formation and rapid progress of our Eden BioCell joint venture. We look forward to adding his deep experience and perspective as a valuable resource to our Board.”

Mr. Huang added, “My career focus has been to identify the best potential technology platforms for investment and to develop those I believe can reach the most patients. We have long sought to identify a viable solution to the problems of cost and manufacturing complexity in the CAR-T space. I believe that Ziopharm’s approach, with its non-viral DNA plasmid-based Sleeping Beauty platform, has the best chance to stand apart from the competition to solve these issues. I am delighted to join Ziopharm’s Board of Directors and look forward to working with Laurence and the experienced Ziopharm team.”

Mr. Huang joined KPCB China as a Managing Partner in 2011 and focused on the firm’s life sciences practice. Prior to joining KPCB, he was a Managing Partner at Vivo Ventures, a venture capital firm specializing in life sciences investments. While at Vivo, he led numerous investments in China. Prior to joining Vivo in 2007, Mr. Huang was President of Anesiva, a biopharmaceutical company focused on pain-management treatments. During his 20-year career in the pharmaceutical and biotech industry, Mr. Huang held senior roles in business development, sales, marketing and R&D with Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp (acquired by Johnson & Johnson). Mr. Huang also built GenScript, including Legend Biotech from a small U.S. venture backed company into a revenue-generating company with a multi-billion valuation on the Hong Kong Stock Exchange and Nasdaq.

Seite 1 von 3
Ziopharm Oncology Aktie jetzt ab 0€ handeln - auf Smartbroker.de

Diesen Artikel teilen

0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren



Meistgelesene Nachrichten des Autors


Diskussionen zu den Werten